Tadashi Toki

发表

A novel inhibitor of I-kappaB kinase beta ameliorates experimental arthritis through downregulation of proinflammatory cytokines in arthritic joints.

Shinji Tanaka, M. Yokoyama, K. Morishita, 2014, Biological & pharmaceutical bulletin.

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

M. Yamaguchi, M. Murakami, H. Hamada, 2021, Molecular Cancer Therapeutics.

Lipopolysaccharide accelerates collagen‐induced arthritis in association with rapid and continuous production of inflammatory mediators and anti‐type II collagen antibody

Shinji Tanaka, K. Morishita, T. Akimoto, 2013, Microbiology and immunology.

Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.

Shinji Tanaka, K. Morishita, S. Iimura, 2010, Bioorganic & medicinal chemistry letters.

Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.

Shinji Tanaka, M. Yokoyama, K. Morishita, 2011, Bioorganic & medicinal chemistry letters.

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2020 .

Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold.

Makoto Suzuki, H. Inoue, K. Nakayama, 2019, ACS medicinal chemistry letters.

Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with In Vivo Anti-Tumor Activity.

S. Tsutsumi, Makoto Suzuki, H. Inoue, 2019, Journal of medicinal chemistry.

Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.

Shinji Tanaka, M. Yokoyama, K. Morishita, 2011, Bioorganic & medicinal chemistry letters.